Hyundai Pharm Co., Ltd.

Hyundai Motor Company

Kia Motors Corporation

Kia Corporation

Daesung Electric Co., Ltd.

Kyu Hwan Lee

Jin Woong Kim

Jae Hyun Kim

Jin Wook Yang

Han Kyu Lee

Chang Mo Son

Daehoon Kim

Jaekeol Rhee

Hyung-Ho Choi

Tae-Young Ha

Dae Hoon Kim

Jinwoong Kim

Sung Hyun Kang

Jeongun Hwang

Hanum Min

Jeong Un Hwang

Jae Keol Rhee

Hyung Ho Choi

Su Kyoung Choi

Eun Young Kim

An electro mechanical brake (EMB) emergency braking device includes an EMB driving unit such as an electric motor that generates driving force; an emergency braking driving unit that generates emergency braking driving force, and may include a pneumatic actuator; and braking force generating unit that generates braking force by receiving one of the driving force or the emergency braking driving force, where the EMB driving unit and the emergency braking driving unit may generate the driving force or the emergency braking driving force from different power sources.

Electromechanical brake emergency braking device for vehicle and emergency braking method

The present invention relates to a pharmaceutical composition for preventing or treating metabolic diseases, in which a novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative and at least another active ingredient, which is selected from the group consisting of dipeptidyl peptidase-4 (DPPIV) inhibitor-based, sulfonylurea-based, thiazolidinedione (TZD)-based, biguanide-based, and sodium/glucose cotransporter 2 (SGLT2) inhibitor-based drugs, may be administered in combination or in the form of a composite preparation. The use of the composition of the present invention can provide a remarkably excellent blood sugar reducing effect in various animal diabetic disease models, and the composition of the present invention can be favorably used as a pharmaceutical composition for preventing or treating metabolic diseases, such as obesity, diabetes type I, diabetes type II, glucose intolerance symptoms, insulin resistance symptoms, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, and syndrome X.

Composite preparation, containing novel 3-(4--(benzyloxy)phenyl)hex-4-inoic acid derivative and another active ingredient, for preventing or treating metabolic diseases

The present invention relates to a cyclohexene derivative, a preparation method thereof, and a pharmaceutical composition for preventing or treating metabolic disease containing the cyclohexene derivative as an active ingredient. The cyclohexene derivative according to the present invention increases the intracellular activity of cyclic adenosine monophosphate (cAMP) by activating G protein-coupled receptor 119 (GPR-119) and simultaneously exhibits weight loss and hypoglycemic effects by inducing the release of glucagon-like peptide-1 (GLP-1), which is a neuroendocrine protein, and thus can be useful as a pharmaceutical composition for preventing or treating metabolic diseases such as obesity, type 1 diabetes, type 2 diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia and syndrome X.

Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient

The present invention relates to a novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, a preparation method thereof, and a pharmaceutical composition comprising the same as an active ingredient for the prevention and treatment of metabolic disease. The novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention has excellent activities of activating GPR40 protein and promoting insulin secretion accordingly but has no toxicity when co-administered with other drugs. That is, the novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention can be co-administered with other drugs and can promote the activation of GPR40 protein significantly, so that the composition comprising the same as an active ingredient can be efficiently used as a pharmaceutical composition for the prevention and treatment of metabolic disease such as obesity, type I diabetes, type II diabetes, incompatible glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, and syndrome X, etc.

3-(4-(benzyloxy)phenyl)hex-4-ynoic acid derivative, method of preparing same and pharmaceutical composition for preventing and treating metabolic disease including same as effective ingredient

The present invention relates to a haptic scroll wheel switch for a vehicle which includes a haptic wheel holder, a haptic wheel, a motor, and an encoder slit. The haptic wheel is rotatably installed in the haptic wheel holder and has a bevel gear unit formed on its one side. The motor is installed in the haptic wheel holder and has a driving shaft and an encoder slit installed on its both ends. More specifically, the driving shaft and the encoder slit are rotated and driven while operating in conjunction with the motor. Furthermore, a pinion gear is fixed to the driving shaft of the motor and geared with the bevel gear of the haptic wheel so that the pinion gear is operated in conjunction with the bevel gear, and a printed circuit board is used in conjunction with a sensor for detecting a rotation of the encoder slit.

Haptic scroll wheel switch for vehicle

Growing community of inventors

Gyeonggi-do, South Korea

Kyu Hwan Lee